semaglutide and cardiovascular Heart disease: may reduce risk by up to 20% in 6 months Evaluating the Cardiovascular Benefits of

GLP-1s are all the rage right now, in terms of reducing weight

Abdalla MA, et al

And yes, we end with a couple hot topic questions that came straight from social media: everything from fresh air habits at home to the debate around GLP-1 medications and how they may (or may not) affect cravings beyond food

Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1960-62 Through 2007-2008 (NCHS, 2010)

This is supported by the fact that several ME/CFS outbreaks have occurred in the same geographical region simultaneously (12)

Building Strategic Partnerships for Program Success Strategic collaborations can strengthen both patient outcomes and business growth